Leyh R G, Fischer S, Ruhparwar A, Haverich A
Abteilung für Thorax-, Herz- und Gefässchirurgie Medizinische Hochschule Hannover Carl-Neuberg-Str. 1, 30623 Hannover, Germany.
Z Kardiol. 2002 Apr;91(4):297-303. doi: 10.1007/s003920200030.
We report on the case of a 24-year-old pregnant woman with acute mechanical mitral valve thrombosis due to a treatment failure of low molecular weight heparin (LMWH) for permanent anticoagulation following mechanical valve replacement. Initially, our patient was put on oral warfarin for anticoagulation, but when her pregnancy was perceived the anticoagulation regimen was switched to daily subcutaneous administration of LMWH in order to minimize the risk of warfarin-induced embryopathy. During her 24th week of gestation she developed acute life-threatening pulmonary edema and hemodynamic instability, which was caused by an acute thrombosis of her artificial mitral valve. In an emergency operation the thrombozed valve was replaced by a porcine biological heart valve. The patient recovered uneventfully and gave birth to a healthy child in her 35th gestational week by cesarean section. In addition we discuss the rationale of different anticoagulation regimens with regard to maternal and fetal outcome with special consideration of LMWH as an alternative strategy to oral anticoagulation during pregnancy in women with mechanical heart valves.
我们报告了一例24岁的孕妇,该孕妇因机械瓣膜置换术后低分子量肝素(LMWH)用于长期抗凝治疗失败而发生急性机械性二尖瓣血栓形成。最初,我们的患者接受口服华法林抗凝治疗,但在发现她怀孕后,抗凝方案改为每日皮下注射LMWH,以尽量降低华法林所致胚胎病的风险。在她妊娠第24周时,她出现了急性危及生命的肺水肿和血流动力学不稳定,这是由人工二尖瓣急性血栓形成所致。在急诊手术中,血栓形成的瓣膜被猪生物心脏瓣膜替代。患者恢复顺利,并在妊娠第35周通过剖宫产分娩了一个健康的婴儿。此外,我们还讨论了不同抗凝方案对母婴结局的理论依据,并特别考虑了LMWH作为机械心脏瓣膜置换术后孕妇口服抗凝替代策略的情况。